16 March 2023 - State policy makers and purchasers in California are uniquely positioned to further integrate comparative effectiveness research ...
15 March 2023 - Informed by expert advisory group and input from external stakeholders, white paper highlights on-going need to ...
10 March 2023 - This article provides systematic evidence on the share of the value of health generated by drugs and ...
10 March 2023 - Increases in drug prices and drug spending are of concern to health systems worldwide. This has naturally ...
9 March 2023 - Report will be subject of CTAF meeting in September 2023; draft scoping document open to public ...
1 March 2023 - Currently available evidence is rated as promising but inconclusive to determine whether lecanemab provides a net health ...
21 February 2023 - Independent appraisal committee voted that evidence is not adequate to demonstrate a superior net health benefit ...
16 February 2023 - The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of resmetirom ...
23 January 2023 - Independent appraisal committee voted that evidence is not yet adequate to demonstrate a net health benefit ...
17 January 2023 - During ICER’s assessment, five payers revised policies for 11 medicines in ways that bring coverage into ...
22 December 2022 - Registration now open for 5 January “Early Insights” webinar. ...
22 December 2022 - Fair pricing benchmarks suggest upper bounds for price of Roctavian at approximately $1.9 million and for Hemgenix ...
21 December 2022 - Evidence is rated as insufficient to differentiate the net health benefit between ublituximab and other monoclonal antibodies; ...
20 December 2022 - New data suggests Paxlovid will achieve common thresholds of cost effectiveness if priced between $563-$906 per treatment ...
1 December 2022 - Evidence is rated as promising but inconclusive to determine whether fezolinetant provides a net health benefit for ...